The Pharma Data

MARCH 8, 2021

The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. About Molnupiravir.

Trials 69

Trials Virus RNA Research Laboratories 69

The Pharma Data

DECEMBER 15, 2020

A healthy immune system defends the body against disease and other conditions. Autoimmune disease impacts different parts of the body, weakening functionality. Researchers are aware of more than 80 diseases that occur when the immune system attacks the body’s own organs, tissues and cells. It may be life-threatening.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

The Pharma Data

JANUARY 26, 2021

26, 2021 — The first known U.S. “We know that even as we work hard to defeat COVID-19, the virus continues to evolve as all viruses do,” Minnesota Health Commissioner Jan Malcolm said in a statement. Centers for Disease Control and Prevention. © 2021 HealthDay. Posted: January 2021. Professional.

Virus 52

Virus Disease Research 52

The Pharma Data

JANUARY 13, 2021

13, 2021 — The bacteria in your gut may play a role in the severity of COVID-19 infection and the strength of your immune system response, a new study suggests. “Restoration of the missing beneficial bacteria might boost our immunity against SARS-CoV2 virus and hasten recovery from the disease,” she said.

Virus 52

Virus Hospitals Disease Research 52

The Pharma Data

SEPTEMBER 8, 2021

Roche to acquire the TIB Molbiol Group with the expectation to close in fourth quarter of 2021. TIB Molbiol excels in ultra-rapid assay development for emerging infectious disease, strongly demonstrated during the COVID-19 pandemic. The majority of assays are used to test for infectious diseases.

Virus 52

Virus Assay Development Disease Research 52

The Pharma Data

JANUARY 11, 2021

11, 2021 — As the rollout of the COVID-19 vaccines continues, scores of questions are emerging. The COVID-19 vaccines work by teaching the immune system to protect against the virus, experts said. Neither of the two vaccines approved in the United States — made by Pfizer-BioNTech and Moderna — contains the live virus.

Vaccine 52

Vaccine Virus DNA Doctors 52

The Pharma Data

JANUARY 13, 2021

13, 2021 — People flying to the United States will soon need to show proof of a negative COVID-19 test result, the U.S. Centers for Disease Control and Prevention said Tuesday. It is likely that the recently identified version of the virus from the United Kingdom is “probably in every state or most states.

Virus 52

Virus Disease 52

The Pharma Data

SEPTEMBER 5, 2021

Under the agreement, AstraZeneca commits to deliver 60 million doses of the vaccine by the end of the third quarter 2021, 75 million by the end of the fourth quarter 2021 and 65 million by the end of the first quarter 2022. Legal proceedings by the European Commission against AstraZeneca were initiated in Brussels on 21 April 2021.

Vaccine 52

Vaccine Virus Clinical Trials Trials 52

The Pharma Data

JANUARY 8, 2021

8, 2021 — Moderna CEO Stéphane Bancel said the company’s COVID-19 vaccine may prevent infection for years, CBS News reported Thursday. Centers for Disease Control and Prevention says that because reinfection is possible with COVID-19, even people who have already had the virus should still receive the vaccine.

Vaccine 52

Vaccine Virus Disease 52

The Pharma Data

JANUARY 31, 2021

Clover plans to initiate a global phase 2/3 trial in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

JANUARY 14, 2021

14, 2021 — One month after the United States began what has become a troubled rollout of a national COVID-19 vaccination campaign, the effort is finally gathering real steam. Centers for Disease Control and Prevention reported Wednesday. © 2021 HealthDay. Posted: January 2021. Professional. THURSDAY, Jan.

Vaccine 52

Vaccine Virus Research Disease 52

The Pharma Data

AUGUST 16, 2021

During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages. Clearance of the virus in the lungs and nasal passages of the animals was tested following challenge infection with the original virus.

Immune Response 52

Immune Response Vaccine Virus RNA 52

The Pharma Data

JANUARY 31, 2021

Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax’s CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. EMERYVILLE, Calif. and CHENGDU, China , Feb.

Vaccine 52

Vaccine Trials Virus RNA 52

The Pharma Data

JULY 8, 2021

People who receive mRNA COVID-19 vaccines are up to 91 percent less likely to develop the disease than those who are unvaccinated, according to a new nationwide study of eight sites, including Salt Lake City. 13, 2020 and April 10, 2021. Detection of the virus was reduced by 70% percent among those with breakthrough infections, from 8.9

Vaccine 52

Vaccine Virus Nurses Hospitals 52

The Pharma Data

NOVEMBER 17, 2021

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. Data on File Number: REF-131228, 10 November, 2021. Available at: [link] [Accessed August 2021] 6.

Vaccine 52

Vaccine Clinical Trials Virus Licensing 52

The Pharma Data

JANUARY 15, 2021

15, 2021 (American Heart Association News) — Experts have a simple answer for heart and stroke patients questioning whether they need a COVID-19 vaccination. That’s what we want to happen in order for our bodies to make antibodies that will prevent us from getting sick if we encounter the virus again.” FRIDAY, Jan.

Vaccine 52

Vaccine Virus Immune Response Disease 52

The Pharma Data

JUNE 25, 2021

In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria. 37, first identified in Peru (21%) and B.1.621,

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

JANUARY 4, 2021

Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target. 05, 2021 (GLOBE NEWSWIRE) — ViGeneron GmbH , a gene therapy company, today announced a global collaboration and licensing agreement with Biogen Inc. MUNICH, Germany, Jan.

Therapies 52

Therapies Virus Disease Licensing 52

The Pharma Data

JANUARY 20, 2021

20, 2021 — The Abbott BinaxNOW COVID-19 Ag Card (BinaxNOW) rapid antigen test has lower sensitivity than reverse transcription-polymerase chain reaction (RT-PCR) for detecting severe acute respiratory syndrome coronavirus 2 infection, according to research published in the Jan. © 2021 HealthDay. Posted: January 2021.

Virus 52

Virus Disease Research 52

The Pharma Data

JANUARY 5, 2021

5, 2021 — There is some onward transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from household contacts released from quarantine after seven or 10 days, according to research published in the Jan. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report. © 2021 HealthDay.

Virus 52

Virus Disease Research 52

The Pharma Data

JANUARY 4, 2021

4, 2021 — If a second dose of the first COVID-19 vaccine is not available or the maker is not known, then another vaccine may be used, new British guidelines say, The New York Times reported Sunday. © 2021 HealthDay. Posted: January 2021. MONDAY, Jan. The new guidance contradicts those in the United States, where the U.S.

Vaccine 52

Vaccine Virus Production Science 52

The Pharma Data

JUNE 26, 2021

JUNE 22 , 2021. The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. Additional pulmonary diseases are being evaluated in discovery-stage research programs that utilize a proprietary lung delivery platform.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JULY 28, 2021

The analysis included 945,941 mRNA participants (778,534 with two doses), 426,272 Vaxzevria participants, conducted between 27 December 2020 and 19 May 2021. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

Vaccine 52

Vaccine Virus Science Disease 52

The Pharma Data

JULY 6, 2021

If a virus is disease-causing, the right mutation can allow the virus to escape the immune response by changing the viral pieces the immune system uses to recognize the virus as a threat, pieces scientists call epitopes. ” You can think of a virus’s structure like the design of a house, explains Nathan. .

Vaccine 52

Vaccine Virus Research Immune Response 52

The Pharma Data

AUGUST 1, 2021

It is not known whether the impairment, such as forgetfulness and language difficulty, will be progressive, said Gabriel de Erausquin, MD, PhD, a neurologist with the health science center’s Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases. Presented at the Alzheimer’s Association International Conference, July 29, 2021.

Virus 52

Virus International Science Disease 52

The Pharma Data

AUGUST 16, 2021

Vaccination is our most effective means of preventing COVID-19 infection – especially severe disease and hospitalization – and its profound impact on protecting lives is indisputable. We continuously strive to stay at least one step ahead of the virus. today announced that they have submitted Phase 1 data to the U.S. In the U.S.,

Vaccine 52

Vaccine FDA Virus Immune Response 52

The Pharma Data

JANUARY 8, 2021

8, 2021 — As Americans await their COVID-19 shot, a new study of a different vaccine shows the power of Facebook posts in fueling “anti-vax” resistance to immunization. Centers for Disease Control and Prevention. © 2021 HealthDay. Posted: January 2021. FRIDAY, Jan. It can cause genital warts and cancer.

Vaccine 52

Vaccine Doctors Virus Disease 52

The Pharma Data

MARCH 11, 2021

Expected to enroll 415 participants; interim results expected in Q3 2021. The Companies expect interim results from this trial in the third quarter of 2021. the vaccines global business unit of Sanofi, to develop mRNA vaccines for up to five infectious disease pathogens. Shots on goal in the fight against COVID-19.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JANUARY 29, 2021

29 January 2021 — AstraZeneca’s COVID-19 vaccine has been recommended for conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older. Posted: January 2021. Source: AstraZeneca . Source link.

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

The Pharma Data

JANUARY 29, 2021

29 January 2021 — AstraZeneca’s COVID-19 vaccine has been granted a conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older. Posted: January 2021. Source: AstraZeneca. Source link.

Vaccine 52

Vaccine Clinical Trials Virus Trials 52

Drug Target Review

SEPTEMBER 25, 2024

Notably, TT125-802 stabilised disease and prevented further outgrowth of tumours resistant to standard-of-care treatment. Several patients have experienced disease stabilisation, and one NSCLC patient showed a confirmed partial response. 2021 Oct 11 [cited 2024 Sep 4];13(20):5081. 2021 Apr [cited 2024 Sep 4];2(4):377–91.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

The Pharma Data

JANUARY 14, 2021

14, 2021 — Folks who’ve gotten through a COVID-19 infection might naturally question whether they need to get a coronavirus vaccination when their turn comes. Twenty-five COVID patients were involved in the study, including nine with severe or moderate disease that required hospitalization. © 2021 HealthDay. .

Vaccine 52

Vaccine Trials Virus Hospitals 52

The Pharma Data

DECEMBER 3, 2020

Clover intends to initiate a separate pivotal clinical trial of the S-Trimer vaccine candidate in combination with Dynavax’s advanced CpG 1018 adjuvant plus alum in the first half of 2021. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

Vaccine 52

Vaccine Immune Response Virus RNA 52

The Pharma Data

FEBRUARY 24, 2022

Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted approval for COVIFENZ®, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted). This vaccine is indicated for active immunization to prevent coronavirus disease 2019 (COVID?19)

Vaccine 52

Vaccine Virus Government Disease 52

The Pharma Data

NOVEMBER 23, 2020

. Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine. AstraZeneca.

Vaccine 52

Vaccine Virus Trials Clinical Trials 52

The Pharma Data

JANUARY 31, 2021

1, 2021 12:05 UTC. Virios Therapeutics is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (“FM”). ATLANTA–( BUSINESS WIRE )– Virios Therapeutics, Inc. Forward-Looking Statements.

Immune Response 52

Immune Response Research Therapies Disease 52

The Pharma Data

JULY 12, 2021

The data were presented during the late-breaking clinical trials session at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). In addition, Merck plans to initiate a clinical program to evaluate molnupiravir for post-exposure prophylaxis in the second half of 2021. View the full release here: [link]. “It

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories RNA 52